Cerapedics, led by CEO Glen A. Kashuba and based in Westminster, Colo., develops and commercializes a proprietary biomimetic small peptide (P-15) technology platform. Its core product, i-FACTOR Peptide Enhanced Bone Graft, is a biologic bone that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. The company received Premarket Approval (PMA) from the U.S. Food & Drug Administration for use of i-FACTOR in anterior cervical discectomy and fusion (ACDF) procedures. Cerapedics has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion (TLIF) surgery. The company intends to use new financing to accelerate commercialization and a U.S. lumbar trial for i-FACTOR. Cerapedics is a Westminster, CO-based orthobiologics company developing and commercializing bone graft substitute products for the treatment of orthopedic injuries. The company is focused on a proprietary synthetic small peptide (P-15) technology platform. Its flagship product, i-FACTOR Peptide Enhanced Bone Graft, incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. That mechanism is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. i-FACTOR is an FDA-approved product for Anterior Cervical Discectomy and Fusion (ACDF). The company is led by CEO Glen Kashuba and is pursuing broader commercialization and additional clinical study applications. Cerapedics develops and commercializes a proprietary synthetic small peptide (P-15) technology platform for orthopedic bone grafts. Its lead product, i-FACTOR Peptide Enhanced Bone Graft, incorporates a small peptide as an attachment factor to stimulate natural bone healing. i-FACTOR received FDA approval in November 2015 for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. The company plans to use new financing to expand commercialization of i-FACTOR and to further develop its P-15 technology for fusion in the lumbar spine. Cerapedics is led by CEO Glen Kashuba and is based in Westminster, Colorado. Recent financing activity reflects ongoing efforts to commercialize its technology and advance product development. Cerapedics develops and commercializes a proprietary synthetic small peptide (P-15) technology platform and the i-FACTOR biologic bone graft, which uses a small peptide as an attachment factor to stimulate bone healing. The company filed a Premarket Approval (PMA) application with the U.S. Food & Drug Administration for i-FACTOR in September 2014. Cerapedics plans to use recent financing to advance i-FACTOR's development and to expand commercialization in markets outside the U.S. The company is led by CEO Glen Kashuba and is based in Westminster, CO. Financially, the company has completed multiple financings, including the current raise and prior venture debt and equity rounds noted in company reports. Cerapedics is an orthobiologics company focused on developing and commercializing a proprietary synthetic small peptide (P-15) technology platform. Its lead product, the i-FACTOR bone graft, incorporates a small peptide as an attachment factor to stimulate the natural bone healing process and is described as the only biologic bone graft that uses a small peptide in this way. The company says the mechanism is designed to support safer and more predictable bone formation at a lower cost compared to commercially available bone growth factors. Cerapedics is using the recent financing to support general business operations and to advance its U.S. regulatory process. The company is privately held and is based in Westminster, Colorado. Glen Kashuba is cited as Cerapedics’ CEO in the announcement.

Total raised

$89M

Funding rounds

7

Latest round

Equity

Latest activity

Jul 2018